Epstein Secrets

From: Sultan Bin Sulayem To: Jeffrey Epstein <[email protected]> Subject: Fwd: FDA Approved a Potent and Pricey Cholesterol lowering drug today Date: Fri, 24 Jul 2015 20:37:24 +0000 Have

From: Sultan Bin Sulayem To: Jeffrey Epstein <[email protected]> Subject: Fwd: FDA Approv

From: Sultan Bin Sulayem To: Jeffrey Epstein <[email protected]> Subject: Fwd: FD

ing a meeting convened by the FDA to analyze the data on the drug. Some doctors argued its use should be restricted mainly to patients with FH. But Mark Schoenebaum, Evercore ISI's pharmaceutical analyst, says that investors were initially disappointed because they had hoped the FDA would greenlight the drug for

From: Sultan Bin Sulayern Sent: 7/24/2015 8:37:24 PM To: Jeffrey Epstein [[email protected]] Subject: Fwd: FDA Approved a Potent and Pricey Cholesterol lowering drug today Importance: — High Have you heard of this co

Sulayern Sent: 7/24/2015 8:37:24 PM To: Jeffrey Epstein [[email protected]] Subject: Fwd: FDA Approve

owing a meeting convened by the FDA to analyze the data on the drug. Some doctors argued its use should be restricted mainly to patients with FH. But Mark Schoenebaum, Evercore ISI’s pharmaceutical analyst, says that investors were initially disappointed because they had hoped the FDA would greenlight the drug for

From: jeffrey E. [[email protected]] Sent: 7/24/2015 8:47:39 PM To: Sultan Bin Sulayern Subject: Re: FDA Approved a Potent and Pricey Cholesterol lowering drug t

owing a meeting convened by the FDA to analyze the data on the drug. Some doctors argued its use should be restricted mainly to patients with FH. But Mark Schoenebaum, Evercore ISI’s pharmaceutical analyst, says that investors were initially disappointed because they had hoped the FDA would greenlight the drug for